drugset / Trial / NCT01494922

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

NCT01494922 ↗

Phase 2 Completed 14 enrolled Pfizer
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.

Timeline

Start
2011-12-08
Primary completion
2013-09-10
Completion
2013-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject EXC 001 Unknown — Other

Indications